IP Library Granted Patent US 8,236,288
Granted Patent B2
US 8,236,288 · App. 13/345,560 · Granted Aug 7, 2012

Melanin modification compositions and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,288
App. No.
13/345,560
Granted
Aug 7, 2012
Kind
B2
Abstract

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.

Claims (9)

1. A method of lightening skin in an individual in need thereof, comprising administering to the individual in need thereof an effective amount of a composition comprising: a skin-lightening effective amount of a substituted benzaldehyde of from about 0.1% to about 0.5% 4-ethoxybenzaldehyde, from about 0.01% to about 5.0% each of retinol, niacinamide, tetrahexyldecyl ascorbate, glycyrrhiza glabra (licorice) root extract, hexyl resorcinol, and ethyl linoleate, and a pharmaceutically or cosmetically acceptable carrier.

2. The method of claim 1 , wherein the substituted benzaldehyde composition reduces melanin distribution from about 10% to about 40%.

3. The method of claim 1 , wherein the composition is topically or transdermally administered to the skin of the individual.

4. The method of claim 1 , wherein the pharmaceutically or cosmetically acceptable carrier is a topical carrier.

5. The method of claim 1 , wherein the pharmaceutically or cosmetically acceptable topical carrier is a water-in-oil emulsion, cream, liquid, gel, oil, paste, ointment, suspension, foam, lotion, oil-in-water emulsion, water-in-oil-in-water emulsion, water-in-silicone emulsion, spray or serum carrier.

6. The method of claim 1 , wherein the composition further comprises one or more additional active agents.

7. The method of claim 6 , wherein the additional active agent is an antioxidant, a sunscreen, a sunprotectant, a sunblock, a skin-lightening agent, an anti-inflammatory agent, an anti-acne agent or mixtures thereof.

8. The method of claim 7 , wherein the antioxidant is selected from the group of vitamin E, Coenzyme Q10, idebenone, lycopene, green tea polyphenols, silybin, resveratrol, grape seed extract, Oregon grape root ( Mahonia aquifolium ) extract, pomegranate extract, genistein, pycnogenol, curcumin, curcuminoids, tocopherol, dunaliella salina extract or combinations thereof.

9. The method of claim 7 , wherein the skin-lightening agent is selected from the group of hydroquinone, monobenzyl ether of hydroquinone, azelaic acid, kojic acid, mequinol, retinoids, soy proteins, alpha-hydroxy acids, trichloroacetic acid, salicylic acid, hydroquinone-beta-D-glucopyranoside, paper mulberry, glabridin, 4-isopropylcetchol, aleosin, N-acetyl-4-S-cycteaminylphenol, N-propionyl-4-S-cysteaminylphenol, N-acetyl glucosamine, tranexaminc acid, undecylenoyl phenylalanine, an alpha melanocyte stimulating hormone antagonist, phytic acid, or combinations thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2013
From: SKINMEDICA, INC.
To: ALLERGAN, INC.
Reel/Frame 029752/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2012
From: MEHTA, RAHUL C.; MAKINO, ELIZABETH TSIN HO; SONTI, SUJATHA D.; GARRUTO, JOHN A.
To: SKINMEDICA, INC.
Reel/Frame 028150/0091 →